NCT01546324

Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

Prenatal Diagnosis of Fetal DNA Isolated From Maternal Plasma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 16 (actual)
• Sponsor: Natera, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect blood samples from pregnant women who achieved pregnancy following in-vitro fertilization (IVF) with Natera's preimplantation aneuploidy screening (with or without single gene gene testing). These samples will be used for test development of non-invasive prenatal diagnostic testing.

Detailed description

Eligible subjects will sign a consent form and have blood drawn at approximately 8-17 weeks gestation. Subjects will received $200 reimbursement for providing this blood sample. The collected samples will be used to help develop non-invasive prenatal diagnostic testing using Natera's Parental Support technology which is already commercialized for genetic diagnosis of in-vitro embryos. In this study, the technology will be tested for it's ability to analyze fetal-specific pieces of DNA isolated from the mother's blood. No results of the maternal blood testing will be reported to the subject or to their physicians.

Conditions

• Pregnancy Following IVF With PGS/PGD

Interventions

Type	Name	Description
PROCEDURE	Blood draw	Maternal blood draw at approximately 8-17 weeks gestation.

Timeline

• Start date: 2012-02-01
• Primary completion: 2012-05-01
• Completion: 2013-08-01
• First posted: 2012-03-07
• Last updated: 2013-08-12

Locations

1 site across 1 country: United States